![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
OpGen Inc | NASDAQ:OPGN | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.01 | 0.45% | 2.24 | 2.23 | 2.50 | 2.365 | 2.23 | 2.28 | 3,810 | 23:00:06 |
This presentation includes statements relating to the company's Acuitas® AMR Gene Panel products, Acuitas Lighthouse® Software, FDA cleared QuickFISH® products, and commercialization plans for these products and services. These statements and other statements regarding our future plans and goals constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations. Factors that could cause our results to differ materially from those described include, but are not limited to, our successful development of new products and services, our ability to obtain regulatory clearances and approvals for our products and services, the rate of adoption of our products and services by hospitals and other healthcare providers, the success of our commercialization efforts, the effect on our business of existing and new regulatory requirements, and other economic and competitive factors. For a discussion of the most significant risks and uncertainties associated with OpGen's business, please review our filings with the Securities and Exchange Commission (SEC). You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this presentation and speak only as of the date of this presentation. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
OpGen, Inc. has filed with the SEC a registration statement (File No. 333- 230036) and a preliminary prospectus (the Preliminary Prospectus) for the offering to which this communication relates. Before you invest, you should read the Preliminary Prospectus (including the documents incorporated by reference therein) and other documents we have filed with the SEC for more complete information about us and this offering. You may get these documents for free by visiting EDGAR on the SEC website at www.sec.gov . Alternatively, when they are available, copies of the Preliminary Prospectus may be obtained from Aegis Capital Corp., 810 Seventh Avenue, 18th Floor New York, New York 10019. The most recent Preliminary Prospectus filed with the SEC may be obtained by clicking on the active hyperlink below: https://www.sec.gov/Archives/edgar/data/1293818/000107997319000135/opgen_s1a1.htm
This presentation shall not constitute an offer to sell, or the solicitation of an offer to buy, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction. Neither the SEC nor any other regulatory body has approved or disapproved of our securities or passed upon the accuracy of this presentation.The offering will only be made by means of a prospectus pursuant to a registration statement that is filed with the SEC after such registration statement becomes effective.
NASDAQ/OPGN Offering size: Approximately $6,500,000 (100% Primary) over allotment 15% (100% Primary)
Sole Book-Runner Aegis Capital Corp.
Precision medicine company focused on combatting the global antibiotic resistance crisis by leveraging molecular diagnostics, informatics, and genomic analysis Provider of rapid and actionable information about life threatening drug resistant infections Building global network of customers and partners to improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs Key product Acuitas® AMR Gene Panel can detect five pathogens and 47 resistance genes, predicting resistance for 9 classes of antibiotics Collaborations with industry leaders to support the execution of our commercialization strategy as we work to address a $2 billion potential market for precision medicine MDRO solutions
New York State funding for OpGen and ILÚM to build a sustainable, flexible infectious diseases reporting, tracking and surveillance tool for antimicrobial resistance that can be applied across the State. The goal is to improve patient outcomes and save healthcare dollars Qiagen Use EZ1 instruments and reagent kits from QIAGEN and sell or place them with customers in the United States for use with the Acuitas® AMR Gene Panel Thermo Fisher ScientificCombine Thermo Fisher’s real-time PCR solutions with OpGen’s genomic analysis and bioinformatics technology to help healthcare providers rapidly and accurately identify bacterial antibiotic susceptibility using resistance gene profiles ilum health solutions Provides mobile precision medicine and Antimicrobial Stewardship solutions that accelerate definitive therapy selection and optimize clinical decision support
Acuitas Lighthouse® Antibiotic Resistance Prediction Final training set data and program update •2 million Acuitas Lighthouse data points evaluated from Merck SMART surveillance network •41 unique prediction algorithms coded into Acuitas Lighthouse reporting engine •Final training set data supporting prediction algorithms1
Acuitas Isolate/Urine indication initial launch •Post FDA clearance promotional activities •Expanded commercial organization South America / Colombia •INVIMA QuickFISH® regulatory clearance •Clinical decision support software opportunity
1 Year OpGen Chart |
1 Month OpGen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions